Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6807 | Ordered by Date (descending)
1 2 3 ... 67 68 69  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
ReCode Therapeutics–SEVERAL: investment, 202003 financing round Series A $80m co-led by OrbiMed Advisors + Colt Ventures 2020-03-26
SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth 2020-03-26
SutroVax–CTI Life Sciences: investment, 202003 financing round Series D totalling $110m incl existing + co-investor CTI Life Sciences 2020-03-26
SutroVax–Foresite Capital: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Foresite Capital 2020-03-26
SutroVax–Frazier: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Frazier Health Care Partners 2020-03-26
SutroVax–Janus Henderson: investment, 202003 financing round Series D totalling $110m incl new + co-lead investor Janus Henderson Investors 2020-03-26
SutroVax–Longitude Capital: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Longitude Capital 2020-03-26
SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi 2020-03-26
SutroVax–Nan Fung: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Pivotal BioVenture Partners 2020-03-26
SutroVax–RA Capital Management: investment, 202003 financing round Series D totalling $110m incl new + co-lead investor RA Capital Management 2020-03-26
SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
SutroVax–Texas Pacific Group: investment, 202003 financing round Series D totalling $110m incl existing + co-investor TPG Growth 2020-03-26
Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections 2020-03-25
Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG 2020-03-24
Astellas–CytomX Therapeutics: antibody cancer drug, 202003– collab $80m upfront + $1.6b milestones + royalties developm bispecific CD3 drugs 2020-03-23
Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties 2020-03-23
Codexis–Back Bay Life Science Advisors: business consulting, 202003 supply service BBLCA strategic + financial advisor for Codexis in deal with Takeda 2020-03-23
Takeda–Codexis: gene therapy, 202003– collab + license agreem gene therapies for rare genetic disorders 2020-03-23
Danaher–Canale Communications: public relations, 202003 service existent for Cepheid by Canale Communciations 2020-03-21
Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR 2020-03-19
BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno 2020-03-18
Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya 2020-03-17
Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors 2020-03-17
MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED 2020-03-17
Pfizer–BioNTech: mRNA-based vaccines, 202003– collab development of COVID-19 vaccine 2020-03-17
Sigilon Therapeutics–SEVERAL: investment, 202003 financing round Series B $80.3m with CPP Investments + Longevity Vision Fund + BlackRock et al. 2020-03-17
Sigilon Therapeutics–Ten Bridge Communications: public relations, 202003 service existent media relations by Ten Bridge 2020-03-17
Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma 2020-03-16
Tempus Labs–Baillie Gifford: investment, 202003 financing round Series G totalling $100m incl investor Baillie Gifford 2020-03-13
Tempus Labs–Franklin Templeton: investment, 202003 financing round Series G totalling $100m incl investor Franklin Templeton 2020-03-13
Tempus Labs–New Enterprise Associates: investment, 202003 financing round Series G totalling $100m incl investor NEA 2020-03-13
Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings 2020-03-13
Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price 2020-03-13
Tempus Labs–T Rowe Price: investment, 202003 financing round Series G totalling $100m incl funds + accounts managed by T Rowe Price 2020-03-13
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Calixar–SEVERAL: investment, 202003 second financing round €2.5m 2020-03-09
Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall 2020-03-09
Zogenix–LifeSci: public relations, 202003 supply service existent investor relations by LifeSci Advisors 2020-03-06
Zogenix–SEVERAL: investment, 202003 public offering $200.22m+30.03m with 8.52m+1.278m shares common stock at $23.5/share 2020-03-06
Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences 2020-03-05
Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m 2020-03-05
BenchSci–Alphabet: investment, 202002 financing round Series B totalling $22m incl existing + co-investor Gradient Ventures 2020-03-04
BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform 2020-03-03
Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED 2020-03-03
Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen 2020-03-03
Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology 2020-03-02
Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital 2020-03-02
Forty Seven–Gilead: investment, 202003– acquisition $4.9b cash tender offer at $95.5/share 2020-03-02
Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic 2020-03-02
Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic 2020-03-02
Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System 2020-03-02
Danaher–Sherlock Biosciences: molecular diagnostics, 202002– collab developm of Cepheid GeneXpert tests using CRISPR-based SHERLOCK technology 2020-02-28
Sherlock Biosciences–1AB Media: public relations, 202002 service existent media relations by 1AB Media 2020-02-28
Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology 2020-02-27
Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US 2020-02-26
FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen 2020-02-25
Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech 2020-02-25
GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties 2020-02-20
Forte Biosciences–Alger: investment, 202002– financing round totalling $14m incl investor Alger 2020-02-19
Forte Biosciences–BVF Partners: investment, 202002– financing round totalling $14m incl investor BVF Partners LP 2020-02-19
Forte Biosciences–OrbiMed: investment, 202002– financing round totalling $14m incl investor OrbiMed 2020-02-19
Forte Biosciences–SEVERAL: investment, 202002– financing round $14m conditional on completion of reverse merger with Tocagen 2020-02-19
Forte Biosciences–Tocagen: investment, 202002– reverse merger in shares with Forte shareholders holding 74.5% of combined company 2020-02-19
Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 2020-02-18
OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m 2020-02-17
NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics 2020-02-13
Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement 2020-02-11
Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners 2020-02-11
Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures 2020-02-11
Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners 2020-02-11
Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France 2020-02-11
Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds 2020-02-11
Stilla Technologies–SEVERAL: investment, 202002 financing round Series B €20m with new investor TUS-Holdings alongside existing investors 2020-02-11
Stilla Technologies–TUS-Holdings: investment, 202002 financing round Series B totalling €20m incl new investor CLIIF Investment Fund of Tuspark Europe 2020-02-11
Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares 2020-02-07
Aimmune Therapeutics–Nestlé: investment, 202002 equity investment $200m by Nestlé Health Science results in 19.9% common stock + 25.6% fully diluted 2020-02-05
MaaT Pharma–BPCE: investment, 202002 financing round Series B totalling €18m incl existing investor Seventure Partners 2020-02-05
MaaT Pharma–Crédit Mutuel-CIC: investment, 202002 financing round Series B totalling €18m incl existing investor Crédit Mutuel Innovation 2020-02-05
MaaT Pharma–SEVERAL: investment, 202002 financing round Series B €18m with SymBiosis + Seventure + Crédit Mutuel Innovation + Biocodex et al. 2020-02-05
MaaT Pharma–SymBiosis LLC: investment, 202002 financing round Series B totalling €18m incl new investor SymBiosis LLC 2020-02-05
BenchSci–F-Prime Capital: investment, 202002 financing round Series B totalling $22m incl new + lead investor F-Prime Capital 2020-02-04
BenchSci–Golden Ventures: investment, 202002 financing round Series B totalling $22m incl existing + co-investor Golden Ventures 2020-02-04
1 2 3 ... 67 68 69  next pagenext page



Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top